How does RhoGAM prevent hemolytic disease of the newborn (HDN)?
Understand the Problem
The question is asking about the mechanism through which RhoGAM, a medication given to Rh-negative mothers during pregnancy, prevents hemolytic disease of the newborn (HDN). It touches on immunology and maternal-fetal blood compatibility issues.
Answer
RhoGAM prevents an Rh-negative mother's antibodies from reacting to Rh-positive red blood cells of her baby.
RhoGAM prevents hemolytic disease of the newborn (HDN) by preventing an Rh-negative mother's antibodies from reacting to Rh-positive red blood cells of her baby.
Answer for screen readers
RhoGAM prevents hemolytic disease of the newborn (HDN) by preventing an Rh-negative mother's antibodies from reacting to Rh-positive red blood cells of her baby.
More Information
RhoGAM is usually given around the 28th week of pregnancy and after delivery to prevent sensitization in subsequent pregnancies.
Tips
Common mistakes include misunderstanding the timing of RhoGAM administration, which is critical to its effectiveness. It should be given at the right stages of pregnancy and post-delivery.
Sources
- Hemolytic Disease of the Newborn (HDN) - childrenshospital.org
- Hemolytic Disease of the Newborn (HDN) - Health Encyclopedia - urmc.rochester.edu
- The Science Behind RhoGAM - rhogam.com
AI-generated content may contain errors. Please verify critical information
